Seunghee Kim‐Schulze
Papers
3
Total Citations
83
H-Index
2
About
Seunghee Kim-Schulze is a leading immunologist whose research focuses on harnessing the immune system to treat human papillomavirus-related oropharyngeal cancer (HPVOPC). Her work bridges tumor immunology and precision oncology, with major contributions to de-escalation therapy and immunotherapy integration. She was instrumental in the Sinai Robotic Surgery (SIRS) trial, which demonstrated that upfront transoral robotic surgery followed by reduced-dose adjuvant therapy can maintain high survival rates while minimizing toxicity for HPVOPC patients—a paradigm-shifting approach cited over 60 times. Kim-Schulze also pioneered the use of ADXS11-001, a *Listeria*-based immunotherapy targeting HPV E7 antigens, in a “window of opportunity” trial before robotic surgery. Her studies revealed that this treatment enhances HPV-specific T cell immunity and reshapes local and peripheral T cell diversity, offering a novel strategy to boost antitumor responses. With cumulative citations reflecting her impact on clinical oncology, Kim-Schulze’s work is defining less toxic, immune-driven treatments for HPV-positive cancers, making her a key figure in advancing personalized, immunotherapy-based care for head and neck malignancies.
Research Focus
Key Achievements
Top Papers
- 1
- 2
- 3